Abstract
Photochemotherapy with methoxsalen (8-methoxypsoralen) and long wavelength ultraviolet (UV) radiation (referred to as ‘PUVA’ for psoralen plus UVA) is commonly used to treat psoriasis and vitiligo. These vastly different diseases respond to the therapy by different mechanisms even though the immediate effects of the therapy — the photomodification of cellular biomolecules — is the same for each. Because psoriasis is not cured by PUVA, patients receive many treatments over their lifetime and have a significantly increased risk for the development of skin cancers (primarily squamous cell carcinomas). In this article the basic aspects of psoralen photobiology are reviewed briefly. Several recent studies describing the incidence of skin cancer in UVA treated psoriasis cohorts are comparatively reviewed. In addition the impact of the analysis of mutations in the tumor suppressor gene, p53, are summarized. An unexpected mutation spectrum (very few PUVA type T→A transversions and frequent UVB solar signature C→T transitions) suggest that effects other than direct DNA photoadduct formation may be at play. These analyses suggest that it may be possible to improve the therapeutic efficacy of PUVA by a careful evaluation of the mode of delivery. In this review the science behind PUVA is summarized. In addition, the incidence of skin cancer as a long term consequence of repeated treatments is surveyed. To relate clinical observations to molelcular events, the nature of p53 mutations found in skin cancers from psoriasis patients is also analyzed. Finally some suggestions for improving the delivery of PUVA therapy are presented.
Similar content being viewed by others
Notes
These base reactivity preferences are based on the analysis of photoadduct formation in solutions of methoxsalen and DNA in vitro. Cellular reaction patterns could differ due to the packaging of DNA in the nucleus.[15]
Based on the analysis of hprt mutations in diploid human skin fibroblasts, Burger and Simons[33] estimated that the cumulative number of methoxsalen plus UVA mutagenic events expected to occur in human skin was 1.2 × 10−5 per photochemotherapy session and 1.3 × 10−2 per cell during 30 years of maintenance (100 times greater than the spontaneous rate of mutations).
References
Fitzpatrick T.B., Pathank M.A. Research and development of oral psoralen and longwave radiation photochemotherapy: 2000 B.C.–1982 A.D. Natl Cancer Inst Monogr 1984; 66: 3–11
El Mofty A.M. A preliminary clinical report on the treatment of leukoderma with Ammi majus linn. JR Egypt Med Assn 1948; 31: 651–665
Bethea D., Fullmer B., Syed S, et al. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci 1999: 19: 78–88
Peritz A.E., Gasparro F.P. Psoriasis, PUVA and skin cancer— molecular epidemiology: the curious question of T→A transversions. J Investig Dermatol Symp Proc 1999; 4: 11–16
Morison W.L., Baughman S.D., Day R.M., et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595–598
Halpern S.M. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 2000; 142: 22–31
Koo J.Y. Current consensus and update on psoriasis therapy: a perspective from the US. J Dermatol 1999; 26: 723–733
Karasek M.A. Progress in our understanding of the biology of psoriasis. Cutis 1999; 64: 319–322
Nickoloff B.J. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 133: 1104–1110
Honigsmann H., Fitzpatrick T.B., Pathak M.A., et al. Oral photochemotherapy with psoralen and UVA (PUVA): principles and practice. In: Fitzpatrick T.B., Eisen A.Z., Wolf K., editors. Dermatology in general medicine. New York: McGraw- Hill, 1987; 1728–1754
Parrish J.A., Fitzpatrick T.B., Tannenbaum L., et al. Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 1974; 291: 1207–1211
Edelson R.L., Berger C.L., Gasparro F.P., et al. Treatment of cutaneous T cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297–303
Moor A.C.E., F.P. Gasparro. Biochemical aspects of psoralen photochemotherapy. Clin Dermatol 1996; 4: 353–356
Musajo L., Rodighiero G., Breccia A., et al. The photoreactions between DNA and the skin-photosensitizing furocoumarin studied using labeled bergapten. Experientia 1968; 22: 75–78
Boyer V., Moustacchi E., Sage E. Sequence specificity in photoreaction of various psoralen derivatives with DNA: role in biological activity. Biochemistry 1988: 19: 3011–3018
Yun M.H., Choi S.J., Shim S.C. A novel photoadduct of 4,5t′,8-trimethylpsoralen and adenosine. Photochem Photobiol 1992; 55: 457–4560
Liu Z., Lu Y., Lebwohl M., et al. PUVA (8-methoxypsoralen plus ultraviolet A) induces the formation of 8-hydroxy-2′-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Rad Biol Med 1999; 27: 127–133
Kreutzer D.A., Essigmann J.M. Oxidized, deaminated cytosines are a source of C?T transitions in vivo. Proc Natl Acad Sci USA 1998; 95: 3578–3582
Frederiksen S., Hearst J.E. Binding of 4t′-aminomethyl-4,5t′,8-trimethylpsoralen to DNA, RNA and protein in HeLa cells and Drosophila cells. Biochem Biophys Acta 1979; 563: 343–355
Johnson R., Staiano-Coico L., Austin L., et al. PUVA treatment selectively induces a cell cycle block and subsequent. apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63: 566–571
Vallat V.P., Gilleaudeau P., Battat L. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283–296
Strauss G.H., Albertini R.J., Krusinski P.A., et al. 6-Thioguanine resistant peripheral blood lymphocytes in human s following psoralen, long-wave ultraviolet light (PUVA) therapy. J Invest Dermatol 1979; 73: 211–216
Sage E., Bredberg A. Damage distribution and mutation spectrum: the case of 8-methoxy- psoralen and UVA in mammalian cells. Mutat Res 1991; 263: 217–222
Yang S.C., Lin J.G., Chiou C.C., et al. Mutation specificity of 8-methoxypsoralen plus two doses of UVA irradiation in the hprt gene in diploid human fibroblasts. Carcinogenesis 1994; 15: 201–207
Bredberg A., Nachmansson N. Psoralen adducts in a shuttle vector plasmid propagated in primate cells: high mutagenicity of DNA cross-links. Carcinogenesis 1987; 8: 1923–1927
Gunther E.J., Yeasky T.M., Gasparro F.P., et al. Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by monoadducts as well as cross-links. Cancer Res 1995; 55: 1283–1288
Lindelof B., Sigurgeirsson B. PUVA and cancer: a case-control study. Br J Dermatol 1993; 129: 39–41
Stern R.S., Laird N., Melski J., et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156–1161
Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759–2764
Stern R.S., Liebman E.J., Väkevä L., et al. Oral psoralen and ultraviolet A (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. J Natl Cancer Inst 1998; 90: 1278–1284
Studniberg H.M., Weller P. PUVA, UVB, psoriasis and nonmelanoma cancer. J Am Acad Dermatol 1993; 29: 1013–1022
Tokura Y., Edelson R.L., Gasparro F.P. Formation and removal of 8-MOP-DNA photoadducts in keratinocytes: effects of calcium concentration and retinoids. J Invest Dermatol 1991; 96: 942–949
Burger P.M., Simons J.W.I.M. Mutagenicity of 8-methoxypsoralen and long-wave ultraviolet irradiation in haploid human skin fibroblasts: an improved risk estimate in photochemotherapy. Mutat Res 1979; 63: 371–380
Stern R.S., Nichols K.T., Vakeva L.H., et al. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336: 1041–1045
Hannuksela-Svahn A., Pukkala E., Koulu L., et al. Cancer incidence among finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol 1999; 40: 694–696
Lindelof B., Sigurgeirsson B., Tegner E., et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108–112
Hannuksela-Svahn A., Pukkala E., Laara E., et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587–590
Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999; 141: 497–501
Donath P., Bethea D., Amici L., et al. Low and irreproducible methoxsalen levels in patients receiving photochemotherapy. Arch Dermatol 1999; 135: 604–606
Shephard S.E., Panizzon R.G. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy. Dermatol 1999; 199: 106–112
Guo Z., Okamoto H., Danno K., et al. The effects of non-interval PUVA treatment on Langerhans cells and contact hypersensitivity. J Dermatol Sci 1992; 3: 91–96
Nataraj A.J., Black H.S., Ananthswamy H.N. Signature p53 mutations at DNA crosslinking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci USA 1996; 93: 7961–7965
Wang X.M., McNiff J.M., Klump V., et al. An unexpected spectrum of p53 mutations from squamous cell carcinomas in patients treated with PUVA. Photochem Photobiol 1997; 66: 294–299
Nataraj A.J., Wolf P., Cerroni L., et al. P53 mutations in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA): relative frequency of PUVA- versus UV-signature mutations. J Invest Dermatol 1997; 109: 238–243
Sagher D., Strauss B. Insertion of nucleotides opposite apurine/apyrmidinic sites in deoxyribonucleic acid during in vitro synthesis: uniqueness of adenine nucleotides. Biochem 1983; 22: 4518–4526
Greenblatt M.S., Bennett W.P., Hollstein M., et al. Mutations in p53 tumor suppression gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4578
Monti P., Inga A., Aprile A., et al. p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis 2000; 15: 127–132
Peritz A., Douglass M.C., McNiff J., et al. Analysis of p53 mutations based on microdissection of tumor bioipsies from psoriasis patients treated with PUVA. Photochem Photobiol 1999; 70: 29s–30s
Kripke M.L. Effects of methoxsalen plus near-ultraviolet radiation or mid-ultraviolet radiation on immunologic mechanisms. Natl Cancer Inst Monogr 1984; 66: 247–251
Kumar J.R., Haberman H.F., Ranadive N.S. Comparative studies on the tolerance to photoinduced cutaneous inflammatory reactions by psoralen and rose bengal. J Photochem Photobiol B 1997; 37: 245–253
Miller R.A. Gerontology as oncology. Research on aging as the key to the understanding of cancer. Cancer 1991; 68 Suppl. 11: 2496–2501
Gasparro F.P. Extracorporeal photochemotherapy: clinical aspects and the molecular basis for efficacy. RG Landes Co, Medical Intelligence Unit, 1994
Fischer T., Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol Stockholm 1976; 56: 383–390
Bolognia J.L., Freije L., Amici L., et al. Rectal suppositories of 8-methoxypsoralen produce ewer gastrointestinal side effects than the oral formulation. J Am Acad Dermatol 1996; 35: 424–427
Stolk L., Siddiqui A.H., Kammeyer A., et al. Serum and saliva levels of 8- methoxypsoralen after rectal administration as a micro-enema. Br J Dermatol 1981; 104: 447–451
Billard V., Gambus P.L., Baar J., et al. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans. Br J Clin Pharmacol 1995; 40: 347–360
Knobler R.M., Trautinger F., Graninger W., et al. Parenteral administration of 8- methoxypsoralen in photopheresis. J Am Acad Dermatol 1993; 28: 580–584
Bachynsky M.O., Infeld M.H., Margolic R.L., et al. Psoralen formulation for UV-A photopheresis. Eur Pat Appl EP 392, 429; US Appl 336, 179, 1990
Neild V.S., Scott L.V. Plasma levels of 8-methoxypsoralen in psoriatic patients receiving topical 8-methoxypsoralen. Br J Dermatol 1982; 106: 199–203
Pham C.T., Koo J.Y. Plasma levels of 8-methoxypsoralen after topical paint PUVA. J Am Acad Dermatol 1993; 28: 460–466
Cristofolini M., Recchia G., Boi S., et al. 6-Methylangelicins: new monofunctional photochemotherapeutic agents for psoriasis. Br J Dermatol 1990; 122: 513–524
Tanew A. Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis. J Am Acad Dermatol 1999; 41: 408–413
Ortel B., Perl S., Kinaciyan T., et al. Comparison of narrow-band (311 nm) UVB and broad-band UVA after oral or bath-water 8-methoxypsoralen in the treatment of psoriasis. J Am Acad Dermatol 1993; 29: 736–740
Filipe P., Emerit I., Youssefl A.A., et al. Oxyradical-mediated clastogenic plasma factors in psoriasis. Increases in clastogenic activity after PUVA. Photochem Photobiol 1997; 66: 497–501
Taylor C.R., Kwangsukstith C., Wimberly J., et al. Turbo-PUVA: dihydroxyacetoneenhanced photochemotherapy for psoriasis: a pilot study. Arch Dermatol 1999; 135: 540–544
Streit V., Wiedow O., Christophers E. Treatment of psoriasis with polyethylene sheet bath PUVA. J Am Acad Dermatol 1996; 35: 208–210
Murphy G.M. Skin cancer in patients with psoriasis-many intertwined risk factors. Br J Dermatol 1999; 141: 1001–1002
Al-Suwaidan S.N., Feldman S.R. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42: 796–802
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gasparro, F.P. The Role of PUVA in the Treatment of Psoriasis. Am J Clin Dermatol 1, 337–348 (2000). https://doi.org/10.2165/00128071-200001060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001060-00002